Hepatitis B Virus
Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chronic Hepatitis B
Published in Hepatitis Weekly, May 5th, 2008
Gilead Sciences, Inc. (Nasdaq:GILD) announced the presentation of detailed 72-week data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread(R) (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. These data will be presented Friday, April 25, at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) currently taking place in Milan, Italy (April 23-27).
Studies 102 and 103 were designed to evaluate treatment with Viread over 240 weeks among patients with HBeAg-negative (presumed pre-core mutant) and HBeAg-positive chronic...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2008-05-05)
More Articles from Hepatitis Weekly
- Hepatitis B Virus
New findings from National Taiwan University in the area of hepatitis B virus described - Hepatitis B Virus
New hepatitis B virus research from P.H.C. Franca et al outlined - Hepatitis B Virus
Research from Charite University yields new findings on hepatitis B virus - Hepatitis B Virus
Researchers at GlaxoSmithKline target hepatitis B virus - Hepatitis B Virus
Researchers from Gazi University, Medical Department report details of new studies and findings in the area of hepatitis B virus - Hepatitis B Virus
Researchers from University of Washington publish new studies and findings in the area of hepatitis B virus - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
